ABVC BioPharma (ABVC) Stock Overview
A clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ABVC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ABVC BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.15 |
| 52 Week High | US$5.48 |
| 52 Week Low | US$0.40 |
| Beta | 0.24 |
| 1 Month Change | -17.62% |
| 3 Month Change | -28.81% |
| 1 Year Change | 264.41% |
| 3 Year Change | -65.32% |
| 5 Year Change | -95.74% |
| Change since IPO | -90.62% |
Recent News & Updates
Recent updates
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt
Mar 13
Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute
Oct 05ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug
Sep 23ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?
Aug 18ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M
Aug 17ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
Jul 13Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute
Jun 30Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?
Apr 04Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Dec 09Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Aug 05Shareholder Returns
| ABVC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.7% | -2.5% | -0.5% |
| 1Y | 264.4% | 25.4% | 16.9% |
Return vs Industry: ABVC exceeded the US Biotechs industry which returned 25.4% over the past year.
Return vs Market: ABVC exceeded the US Market which returned 16.9% over the past year.
Price Volatility
| ABVC volatility | |
|---|---|
| ABVC Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ABVC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABVC's weekly volatility has decreased from 17% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 18 | Uttam Patil | www.abvcpharma.com |
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.
ABVC BioPharma, Inc. Fundamentals Summary
| ABVC fundamental statistics | |
|---|---|
| Market cap | US$50.68m |
| Earnings (TTM) | -US$5.08m |
| Revenue (TTM) | US$797.92k |
Is ABVC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABVC income statement (TTM) | |
|---|---|
| Revenue | US$797.92k |
| Cost of Revenue | US$0 |
| Gross Profit | US$797.92k |
| Other Expenses | US$5.88m |
| Earnings | -US$5.08m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 100.00% |
| Net Profit Margin | -636.31% |
| Debt/Equity Ratio | 14.6% |
How did ABVC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 21:54 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABVC BioPharma, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |
| Marla Marin | Zacks Small-Cap Research |